KTKohichiro Tsuji

Kohichiro Tsuji

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kohichiro Tsuji has a total of 63 co-authors. Here are the top co-authors by number of shared publications:

  • Yasuhiro Ebihara

    Division of Stem Cell Processing, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan

    9 shared publications
  • Tatsutoshi Nakahata

    Department of Pediatrics, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan; and

    8 shared publications
  • Feng Ma

    The University of Tokyo

    7 shared publications
  • Atsushi Manabe

    NEOPLASIA

    4 shared publications
  • Hiroshi Yoshino

    Department of Pediatric Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo

    3 shared publications
  • Mamoru Ito

    Central Institute for Experimental Animals

    3 shared publications

Latest Publications

  • Quantitative polymerase chain reaction detection of CEP110–FGFR1 fusion gene in a patient with 8p11 myeloproliferative syndrome

    by Shohei Yamamoto, Yasuhiro Ebihara, Shinji Mochizuki, Toshiro Kawakita, Seiko Kato, Jun Ooi, Satoshi Takahashi, Arinobu Tojo, Nozomi Yusa, Yoichi Furukawa, et al.


  • Generation of red blood cells from human embryonic/induced pluripotent stem cells for blood transfusion

    by Yasuhiro Ebihara, Feng Ma, Kohichiro Tsuji

    Red blood cell (RBC) transfusion is necessary for many patients with emergency or hematological disorders. However, to date the supply of RBCs remains labile and dependent on voluntary donations. In addition, the transmission of infectious disease via blood transfusion from unspecified donors remains a risk. Establishing a large quantity of safe RBCs would help to address this issue. Human embryonic stem (hES) cells and the recently established human induced pluripotent stem (hiPS) cells represent potentially unlimited sources of donor-free RBCs for blood transfusion, as they can proliferate indefinitely in vitro. Extensive research has been done to efficiently generate transfusable RBCs from hES/iPS cells. Nevertheless, a number of challenges must be overcome before the clinical usage of hES/iPS cell-derived RBCs can become a reality.


  • Open Access

    Generation of Blood Cells from Human Embryonic Stem Cells and Their Possible Clinical Utilization

    by Feng Ma, Wenyu Yang, Yasuhiro Ebihara, Kohichiro Tsuji

  • Open Access

    Reduced dose chemotherapy for acute promyelocytic leukaemia with adult Down syndrome

    by Mayuko Tsuda, Yasuhiro Ebihara, Shinji Mochizuki, Kaoru Uchimaru, Arinobu Tojo, Kohichiro Tsuji


  • Generation of functional erythrocytes from human embryonic stem cell-derived definitive hematopoiesis

    by Feng Ma, Yasuhiro Ebihara, Katsutsugu Umeda, Hiromi Sakai, Sachiyo Hanada, Hong Zhang, Yuji Zaike, Eishun Tsuchida, Tatsutoshi Nakahata, Hiromitsu Nakauchi, et al.

    A critical issue for clinical utilization of human ES cells (hESCs) is whether they can generate terminally mature progenies with normal function. We recently developed a method for efficient production of hematopoietic progenitors from hESCs by coculture with murine fetal liver-derived stromal cells. Large numbers of hESCs-derived erythroid progenitors generated by the coculture enabled us to analyze the development of erythropoiesis at a clone level and investigate their function. The results showed that the globin expression in the erythroid cells in individual clones changed in a time-dependent manner. In particular, embryonic ε-globin-expressing erythroid cells from individual clones decreased, whereas adult-type β-globin-expressing cells increased to ≈100% in all clones we examined, indicating that the cells undergo definitive hematopoiesis. Enucleated erythrocytes also appeared among the clonal progeny. A comparison analysis showed that hESC-derived erythroid cells took a similar differentiation pathway to human cord blood CD34 + progenitor-derived cells when examined for the expression of glycophorin A, CD71 and CD81. Furthermore, these hESC-derived erythroid cells could function as oxygen carriers and had a sufficient glucose-6-phosphate dehydrogenase activity. The present study should provide an experimental model for exploring early development of human erythropoiesis and hemoglobin switching and may help in the discovery of drugs for hereditary diseases in erythrocyte development.


  • Novel Method for Efficient Production of Multipotential Hematopoietic Progenitors from Human Embryonic Stem Cells

    by Feng Ma, Dan Wang, Sachiyo Hanada, Yasuhiro Ebihara, Hirohide Kawasaki, Yuji Zaike, Toshio Heike, Tatsutoshi Nakahata, Kohichiro Tsuji

    We propose a novel method for the efficient production of hematopoietic progenitors from human embryonic stem cells (hESC) via coculture with murine fetal liver-derived stromal cells, in which embryonic hematopoiesis dramatically expands at midgestation. We generated various hematopoietic progenitors in coculture, and this hematopoietic activity was concentrated in cobblestone-like cells derived from differentiated hESC. The cobblestone-like cells mostly expressed CD34 and retained an endothelial cell potential. They also contained hematopoietic colony-forming cells, especially erythroid and multilineage colony-forming cells at high frequency. The multipotential hematopoietic progenitors abundant among the cobblestone-like cells produced almost all types of mature blood cells, including adult-type β-globin-expressing erythrocytes and tryptase/chymase double-positive mast cells. These progenitors showed neither the immature properties of ESC nor the potential to differentiate into endoderm and ectoderm at a clonal level. The coculture system developed for hESC can provide a novel source of hematopoietic and blood cells for applications in cellular therapy and drug screening.


  • Open Access

    RAS-blocking bisphosphonate zoledronic acid inhibits the abnormal proliferation and differentiation of juvenile myelomonocytic leukemia cells in vitro

    by Yoshitoshi Ohtsuka, Atsushi Manabe, Hirohide Kawasaki, Daisuke Hasegawa, Yuji Zaike, Sumiko Watanabe, Takakuni Tanizawa, Tatsutoshi Nakahata, Kohichiro Tsuji

    Juvenile myelomonocytic leukemia (JMML) is a clonal myeloproliferative/myelodysplastic disorder of early childhood with a poor prognosis. JMML cells are characterized by hypersensitivity to granulocyte-macrophage colony-stimulating factor (GM-CSF) caused by a continuously activated GM-CSF receptor–retrovirus-associated sequence (RAS) signal transduction pathway through various molecular mechanisms, resulting in spontaneous GM colony formation in vitro. Bisphosphonate zoledronic acid (ZOL), a RAS-blocking compound, suppressed colony formation from bone marrow (BM) cells of 8 patients with JMML and 5 healthy control subjects without and with GM-CSF (10 ng/mL), respectively, in a dose-dependent manner in clonal culture. At 10 μM ZOL, however, spontaneous GM colony formation from JMML BM cells decreased to 3%, but the formation of G colonies containing granulocytes, but no macrophages, was enhanced, whereas 40% of GM colonies were retained and G colony formation was not affected in culture of normal BM cells with GM-CSF. In suspension culture, cytochemical and flow cytometric analyses showed that 10 μM ZOL also inhibited spontaneous proliferation and differentiation along monocyte/macrophage lineage of JMML BM cells but not the development of normal BM cells by GM-CSF. The inhibitory effect of ZOL on JMML cells was confirmed at a single-clone level and observed even at 3 μM. The current result offers a novel approach to therapy in JMML.


  • Open Access

    Erythropoiesis from acetyl LDL incorporating endothelial cells at the preliver stage

    by Daisuke Sugiyama, Minetaro Ogawa, Imiko Hirose, Thierry Jaffredo, Ken-Ichi Arai, Kohichiro Tsuji

    Erythropoiesis is characterized by 2 waves of production during mouse embryogenesis: a primitive one originating from the yolk sac (YS) and a definitive one produced from both the YS and the embryo proper. How the latter wave is generated remains unclear. To investigate our hypothesis that endothelial cells (ECs) could generate erythroid cells, we designed a method to label ECs at 10 days after coitus. This labeling method associates 2 techniques: an intracardiac inoculation that allows molecules to be delivered into the bloodstream followed by a whole-embryo culture period. DiI-conjugated acetylated low-density lipoproteins (Ac-LDL-DiI) were used to specifically tag ECs from the inside. One hour after inoculation, DiI staining was found along the entire endothelial tree. Fluorescence-activated cell sorter (FACS) analysis revealed that DiI+ cells were CD31+, CD34+, and CD45–, an antigen makeup characteristic of the endothelial lineage. Twelve hours after inoculation, 43% of DiI+ circulating cells belonged to the erythroid lineage. These cells expressed Ter119 and displayed an adult globin chain arrangement; thus they belonged to the definitive lineage as confirmed in erythroid colony formation. The remaining cells likely represent committed white blood cells or multipotent progenitors, as revealed by a mixed-colony formation. Beyond the 29-somite stage, the proportion of DiI+ erythroid cells gradually decreased. These results demonstrate the generation of hematopoietic cells from an endothelial intermediate, using in vivo tracing. We provide evidence for a release of these cells into the circulation and hypothesize that these cells are able to colonize the fetal liver and generate definitive erythrocytes in vivo.


  • Tunica Interna Endothelial Cell Kinase Expression and Hematopoietic and Angiogenic Potentials in Cord Blood CD34+ Cells

    by Mika Wada, Yasuhiro Ebihara, Feng Ma, Hiroshi Yagasaki, Mamoru Ito, Tsuneo Takahashi, Hideo Mugishima, Shigeru Takahashi, Kohichiro Tsuji


  • Development of Human Lymphohematopoiesis Defined by CD34 and CD81 Expression

    by Kohichiro Tsuji, Feng Ma, Dan Wang

    Human blood cells, except for erythrocytes and platelets, express CD81, a member of the transmembrane 4 superfamily (TM4SF). CD81 is also expressed on most of human immature hematopoietic cells, CD34 + cells, which are divided into three populations according to the expression of CD34 and CD81; CD34 + CD81 +, CD34 + CD81 High and CD34 Low CD81 +. Myeloid and lymphoid progenitors exist in the CD34 + CD81 + population, and megakaryocytic progenitors are only in CD34 Low CD81 + population. Erythroid and multipotential progenitors are shared by CD34 + CD81 + and CD34 Low CD81 + populations, but multipotential progenitors in the CD34 + CD81 + population have already lost most of their myeloid potential. NK cells and mast cells can be generated from all three populations. Long-term repopulating (LTR) lymphohematopoietic stem cells are present in the CD34 + CD81 + population. Based on these findings, we propose a model for the development of CD34 + CD81 + lymphohematopoietic stem cells. Along the differentiation cascade from CD34 + CD81 + lymphohematopoietic stem cells, there appear to be pathways to CD34 Low CD81 + or CD34 + CD81 High cells, even if they are indirect. CD34 Low CD81 + pathways define the loss of LTR ability, and lymphoid and myeloid potentials, whereas CD34 + CD81 High pathways represent the exclusive commitment to NK cells and mast cells.